Clinical trial NCT00842998: Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
Official title: A Phase II, Randomized Trial With Single Agent Trastuzumab or Lapatinib in Patients With Metastatic HER2-Overexpressing Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Metastatic Breast Cancer
Keywords: breast cancer
HER2
Trastuzumab
Lapatinib
HER2 gene-amplification
Lead sponsor: Azienda Ospedaliera Ordine Mauriziano di Torino
Sponsor class: OTHER
First posted: 2009-02-12
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the activity of single agent trastuzumab or lapatinib in patients not previously treated for HER-2 positive (FISH positive) metastatic breast cancer. A companion biological study will assess factors correlated with sensitivity or resistance to either one of the compounds


Eligibility criteria: Inclusion Criteria:

* Women aged 18-75 years
* Histologically or cytologically confirmed metastatic disease.
* HER2-Overexpression proven by Fluorescence in Situ Hybridization (FISH).
* Availability of paraffin-embedded block of either primitive tumor and/or biopsy of metastases.
* No prior chemotherapy for metastatic or locally advanced disease. Patients with hormone receptor (oestrogen and/or progesterone) positive breast cancer can be eligible provided that they had received only ONE line of hormonal therapy for metastatic disease.
* For patients undergoing hormonal therapy for metastatic disease, disease progression must be confirmed according to RECIST criteria.
* At least 20% increase in the sum of longest diameters, OR
* Evidence of new metastatic lesions or progression of pre-existing non-target lesions.
* Presence of at least one monodimensionally measurable lesion. Patients without clinically or radiologically proven evidence of disease are not eligible.
* Patients with exclusively skin disease are eligible, provided that the disease evolution under treatment can be photographically documented.
* Patients with involvement of NCS, besides presence of measurable lesions, are eligible provided that:

  * Brain lesion/s has/have been radically resected;
  * Brain lesion/s has/have obtained complete remission following radiation therapy. Complete remission must be documented by TC or RMN.
* At least 4-week interval from end of radiotherapy, hormono- or immunotherapy and enrollment in this study.
* ECOG PS \</= 2 and life expectancy of at least 6 months.
* Liver metastases involving \< 30% of liver volume.
* Adequate hematopoietic, liver and renal function
* Written informed consent.
* Patients with childbearing potential must have negative pregnancy test and must use adequate contraceptive measures during treatment.
* Prior treatment with Trastuzumab as adjuvant therapy is permitted provided that it was completed at least 12 months prior enrollment in this study.

Exclusion Criteria:

* Prior chemotherapy for metastatic disease.
* Active pregnancy or breastfeeding.
* Previous treatment with Lapatinib.
* Previous therapy with mono- or policlonal antibodies for metastatic disease.
* Patients with bone involvement or pleural effusion/ascites as unique localization of disease.
* Patients with dyspnea due to presence of disease (lymphangitis) or requiring oxygen therapy.
* Patients with clinically evident hearth disease and/or active infectious diseases.
* Patients with not resected or not irradiated brain and/or leptomeningeal metastases.
* Prior or actual concurrent neoplasms, with the exception of adequately treated carcinoma della cervice uterina and basal cell or squamocellular carcinoma of the skin.
* Patients with uncontrolled serious illnesses that may compromise the compliance of the patient to the treatment.
* Previous allergic reactions towards any excipient in the composition of Trastuzumab or Lapatinib.
* Use of any experimental drug within 4 weeks prior initiation of study treatment.
* Women with childbearing potential who refuse to use adequate contraceptive measures.
* Patients unable to give written informed consent or are not compliant with treatment.
* Patients with great tumor involvement (\> 30% dof hepatic volume, etc).

Primary outcomes:
measure: Evidence of clinically definite response confirmed by CT or MRI
timeFrame: 8 weeks
Secondary outcomes:
measure: Time to Progression (TTP) and duration of response in patients treated with Trastuzumab
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Orbassano
country: Italy
facility: U.O. Oncologia Medica - Ospedale San Luigi
state: Torino
city: Candiolo , Torino
country: Italy
facility: Institute for Cancer Research and Treatment (I.R.C.C.)
city: Cuneo
country: Italy
facility: U.O. Oncologia Medica
city: Torino
country: Italy
facility: U.O. Oncologia Medica - COES Molinette
Study officials:
affiliation: University of Turin Medical School at AO Ordine Mauriziano di Torino
name: Massimo Aglietta, Full Professor, MD
role: STUDY_CHAIR
affiliation: AO Ordine Mauriziano di Torino
name: Filippo Montemurro, MD
role: PRINCIPAL_INVESTIGATOR
References: